



(51) International Patent Classification:

C07K 16/22 (2006.01) A61P 3/00 (2006.01)
A61K 39/395 (2006.01) A61P 21/00 (2006.01)

(21) International Application Number:

PCT/US2011/037837

(22) International Filing Date:

25 May 2011 (25.05.2011)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/348,559 26 May 2010 (26.05.2010) US
61/372,882 12 August 2010 (12.08.2010) US

(71) Applicant (for all designated States except US): **REGENERON PHARMACEUTICALS, INC.** [US/US];
777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **STITT, Trevor** [US/US]; 251 Briarcliff Road, Ridgewood, NJ 07450 (US). **LATRES, Esther** [US/US]; 123 Sullivan Street, Apt. 3, New York, NY 10012 (US).

(74) Agent: **COTTINGHAM, Frank**; Regeneron Pharmaceuticals, Inc., 777 Old Saw Mill River Road, Tarrytown, NY 10591 (US).


(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))

(54) Title: ANTIBODIES TO HUMAN GDF8



(57) Abstract: The present invention provides isolated human or humanized antibodies or antigen-binding fragments thereof which specifically bind to Growth and Differentiation Factor-8 (GDF8) and block GDF8 activity. The antibodies and antibody fragments of the present invention may be used in therapeutic methods for treating conditions or disorders which are ameliorated or improved by inhibition of GDF8.